EGFR and non-small cell lung carcinoma: Similarly, another phase II study of immunotherapy (toripalimab) plus chemotherapy in patients with EGFR-mutant advanced NSCLC patients found that the combined treatment yielded encouraging PFS (7.0 months) and ORR (50%) (22).